Meeting
2018 ASCO Annual Meeting
Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial.
Authors
Jose Bines
Instituto Nacional de Câncer, Rio De Janeiro, Brazil
Jose Bines , Fabiola Kestelman , Silvania B Siva , Roberta MB Sarmento , Isabele Avila Small , Fabiana R Rodrigues , Pedro S Maroun , Eduardo Millen , Martin H Bonamino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01270373
Citation
J Clin Oncol 36, 2018 (suppl; abstr 575)
DOI
10.1200/JCO.2018.36.15_suppl.575
Abstract #
575
Poster Bd #
67
Abstract Disclosures
Similar Posters
Poster
2011 Breast Cancer Symposium
Effect of oral cyclophosphamide use on pathologic complete response rate in the neoadjuvant treatment of breast cancer.
First Author: M. Luque
Poster
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
First Author: Cheng Wang
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2018 ASCO Annual Meeting
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).
First Author: Wolfgang Janni